Assetmark Inc. Purchases 1,273 Shares of argenx SE (NASDAQ:ARGX)

Assetmark Inc. grew its position in argenx SE (NASDAQ:ARGX) by 29.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,638 shares of the company’s stock after acquiring an additional 1,273 shares during the period. Assetmark Inc.’s holdings in argenx were worth $2,145,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Parkside Financial Bank & Trust bought a new position in shares of argenx in the 3rd quarter valued at $28,000. FNY Investment Advisers LLC bought a new position in argenx during the 4th quarter worth $38,000. Nkcfo LLC raised its position in argenx by 22.1% during the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after purchasing an additional 21 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in argenx during the 4th quarter worth $60,000. Finally, Principal Securities Inc. bought a new position in argenx during the 4th quarter worth $99,000. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Performance

Shares of ARGX opened at $367.07 on Friday. The stock has a 50-day moving average of $378.52 and a 200-day moving average of $400.95. argenx SE has a one year low of $327.73 and a one year high of $550.76.

argenx (NASDAQ:ARGX) last issued its earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to analyst estimates of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the prior year, the business earned ($0.52) earnings per share. As a group, analysts forecast that argenx SE will post -2.73 EPS for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their target price on argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Wells Fargo & Company raised their target price on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Wedbush reaffirmed an “outperform” rating and set a $521.00 target price on shares of argenx in a research report on Thursday, April 18th. JMP Securities lowered their target price on argenx from $471.00 to $468.00 and set a “market outperform” rating for the company in a research report on Friday, May 10th. Finally, Robert W. Baird lowered their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $524.68.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.